We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

The Tetrad BMI, Leptin, Leptin/Adiponectin (L/A) Ratio and CA-15-3 is a Reliable Biomarker of Breast Cancer (leptin)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01643148
Recruitment Status : Completed
First Posted : July 18, 2012
Last Update Posted : July 18, 2012
Universidad Autonoma del Estado de Mexico
Information provided by (Responsible Party):
Hugo Mendieta Zeron, Materno-Perinatal Hospital of the State of Mexico

Brief Summary:


Evaluate body mass index (BMI), leptin, Leptin/adiponectin (L/A) ratio and cancer antigen (CA) 15-3 together as reliable biomarkers for breast cancer.


Consecutive patients aged between 40 - 60 years, with breast disease and informed consent.


Patients' Anthropometric and laboratorial characteristics classified by BMI in the group of cancer and patients with benign breast disease as well as biochemical tests of leptin, adiponectin,CA 15-3, hemoglobin, glucose low-density lipoprotein cholesterol (LDLC), high-density lipoprotein cholesterol (HDLC) levels were obtained as well as a blood sample to analyze CA 15-3 levels with a electrochemiluminescence immunoassay.


Using together leptin, L/A ratio, CA 15-3 and BMI could offer a reliable approach to detect high risk women to develop breast cancer.

Condition or disease
Female Breast Carcinoma

Detailed Description:
Serum levels of leptin, adiponectin and CA 15-3, as well as anthropometric and biochemical parameters were analyzed in 88 female patients attending mammography study. Predictive values of BMI, leptin, L/A ratio and CA 15-3 were determined with 95% confidence interval (CI).

Study Type : Observational
Actual Enrollment : 88 participants
Observational Model: Case Control
Time Perspective: Prospective
Official Title: Phase 1. Collect Samples of Breast Biopsy Patients Treated at the Hospital Radiology Service Maternal Perinatal Monica Pretelini
Study Start Date : January 2011
Primary Completion Date : October 2011
Study Completion Date : July 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
U.S. FDA Resources

breast cancer patients (cases)
36 subjects
36 subjects

Biospecimen Retention:   None Retained

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   40 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Cross-sectional prospective study conducted at the Maternal-Perinatal Hospital "Mónica Pretelini" (HMPMP), State of Mexico Health Institute (ISEM), Toluca, Mexico, from January to October 2011.

Inclusion Criteria:

  • Female patients attending mammography, average age of the fourth and fifth decades.

Exclusion Criteria:

  • Patients with hormonal therapy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01643148

Sponsors and Collaborators
Materno-Perinatal Hospital of the State of Mexico
Universidad Autonoma del Estado de Mexico
Principal Investigator: Jonnathan Guadalupe Santillán Benítez, MSc Autonomus University Of the State Of México
Study Director: Leobardo Manuel Gómez Oliván, PhD Universidad Autonoma del Estado de Mexico
Study Chair: Hugo Mendieta Zeron, PhD Autonomous University of the State of Mexico

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Hugo Mendieta Zeron, PhD, Materno-Perinatal Hospital of the State of Mexico
ClinicalTrials.gov Identifier: NCT01643148     History of Changes
Other Study ID Numbers: DCQ
First Posted: July 18, 2012    Key Record Dates
Last Update Posted: July 18, 2012
Last Verified: July 2012

Keywords provided by Hugo Mendieta Zeron, Materno-Perinatal Hospital of the State of Mexico:
breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type